Top 5 Stock Picks of Chinese Billionaire Lei Zhang

Page 5 of 5

1. BeiGene, Ltd. (NASDAQ:BGNE)

Hillhouse Capital Management’s Stake Value: $1,986,430,000

Percentage of Hillhouse Capital Management’s 13F Portfolio: 25.98%

Number of Hedge Fund Holders: 16

BeiGene, Ltd. (NASDAQ:BGNE), a Chinese biotech company developing drugs for cancer treatment, is the largest holding in Lei Zhang’s Q3 portfolio, with the billionaire owning a $1.98 billion position in the company. The stock accounts for 25.98% of Zhang’s total investments as of the third quarter. 

BeiGene, Ltd. (NASDAQ:BGNE) posted its Q3 results on November 4. EPS in the quarter came in at -$4.46, beating estimates by $0.11. The $206.44 million revenue was up 126.66% year-over-year, outperforming estimates by $20.18 million. 

Bernstein analyst Liang Rebecca on October 18 initiated coverage of BeiGene, Ltd. (NASDAQ:BGNE) with an Outperform rating and a $431 price target, stating that the Chinese biotech and pharmaceutical sector had a global growth potential. 

At the end of September this year, Julian Baker and Felix Baker’s Baker Bros. Advisors is the largest stakeholder in BeiGene, Ltd. (NASDAQ:BGNE), with 11.66 million shares amounting to $4.23 billion. Overall, 16 hedge funds were bullish on BeiGene, Ltd. (NASDAQ:BGNE) as of Q3, with a total stake value of $6.4 billion. 

You can also take a look at Top 10 Stock Picks of Brian Scudieri’s Kehrs Ridge Capital and 10 New Stock Picks of Billionaire Stanley Druckenmiller

Page 5 of 5